Targeting mTOR Recently, Wu et al. tested ten drugs and selected combinations across six RCC PDX models, finding cabozantinib and mTORC1/2 sapanisertib to be the most effective combinational therapies in suppressing tumors from patients who had failed prior TKI and ICI treatments, by blocking the ERK pathway[113]. Here, MTOR is linked to renal cell adenocarcinoma.